Skip to main content

Table 1 Patient and disease characteristics (N = 142)

From: Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma

  Number Percent
Age at start of anti-PD-1/PD-L1 therapy
  < 60 58 40.8
  ≥ 60 84 59.2
Smoker
 No 69 48.6
 Yes 72 50.7
 Unknown 1 0.7
Gender
 Female 41 28.9
 Male 101 71.1
Histology
 Clear cell RCC 120 84.5
 Non-clear cell RCC 22 15.5
Presence of Sarcomatoid
 No 119 83.8
 Yes 22 15.5
 Unknown 1 0.7
Presence of Rhabdoid
 No 134 94.4
 Yes 6 4.2
 Unknown 2 1.4
IMDC risk group at start of anti-PD-1/PD-L1 therapy
 Favorable 26 18.3
 Intermediate 85 59.9
 Poor 31 21.8
Line of therapy
 1 62 43.7
 2 37 26.1
  ≥ 3 43 30.3
Type of anti-PD-1/PD-L1 therapy
 Monotherapy 76 53.5
 Combination therapy
  PD-L1 + VEGF targeted therapy (n = 46)
  PD-1 + VEGF-targeted therapy (n = 9)
  PD-1 + CTLA-4 (n = 7)
  PD-1 + other (n = 4)
66 46.5
  Median range
NLR - baseline 3.9 1.3–42.4
NLR - week 6 4.1 1.1–96.4